[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Klune JR, Zuckerbraun B, Tsung A: Isolated skeletal muscle metastasis following successful treatment of laryngeal cancer: case report. Int Semin Surg Oncol; 2010;7(1):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated skeletal muscle metastasis following successful treatment of laryngeal cancer: case report.
  • We report here on a patient that had been previously treated for squamous cell laryngeal cancer with surgical resection and adjuvant systemic chemotherapy that presented with a metastasis to the rectus abdominis muscle without evidence of recurrent disease at the primary site.
  • After a metastatic workup with PET/CT scan suggested this to be an isolated lesion, surgical excision with negative margins was performed based upon limited treatment options secondary to the location of the tumor and his favorable prognosis suggested by his pathological staging at the time of the initial resection.
  • Here we discuss the incidence of distant metastases from laryngeal cancer and appropriate screening methods.
  • Additionally, skeletal muscle metastases and treatment considerations are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 1):397-401 [10718426.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Dec;11(6):375-8 [11822863.001]
  • [Cites] J Laryngol Otol. 2003 Jan;117(1):85-7 [12590867.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):412-21; discussion 421-2 [14501507.001]
  • [Cites] Endoscopy. 2004 May;36(5):472 [15100974.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Sep;131(3):321-3 [15365554.001]
  • [Cites] Cardiovasc Intervent Radiol. 2005 May-Jun;28(3):377-80 [15886946.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):708-11; quiz 752, 753 [16246684.001]
  • [Cites] J Laryngol Otol. 2005 Oct;119(10):784-90 [16259655.001]
  • [Cites] Clin Exp Dermatol. 2006 Mar;31(2):242-4 [16487102.001]
  • [Cites] Top Magn Reson Imaging. 2007 Jun;18(3):193-202 [17762383.001]
  • [Cites] J Surg Oncol. 2009 Oct 1;100(5):401-3 [19235784.001]
  • [Cites] Head Neck. 1997 Sep;19(6):500-5 [9278758.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1361-5 [9788864.001]
  • [Cites] Head Neck. 2000 Oct;22(7):680-6 [11002323.001]
  • (PMID = 20187979.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2838919
  •  go-up   go-down


2. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, Thomas RR, Grem JL: Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer; 2005;5:116
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
  • BACKGROUND: New chemotherapy regimens for patients with colorectal cancer have improved survival, but at the cost of clinical toxicity.
  • Oxaliplatin, an agent used in first-line therapy for metastatic colorectal cancer, causes acute and chronic neurotoxicity.
  • This study was performed to carefully assess the incidence, type and duration of oxaliplatin neurotoxicity.
  • METHODS: A detailed questionnaire was completed after each chemotherapy cycle for patients with metastatic colorectal cancer enrolled in a phase I trial of oxaliplatin and capecitabine.
  • RESULTS: Eighty-six adult patients with colorectal cancer were evaluated.
  • Acute neuropathy symptoms included voice changes, visual alterations, pharyngo-laryngeal dysesthesia (lack of awareness of breathing); peri-oral or oral numbness, pain and symptoms due to muscle contraction (spasm, cramps, tremors).
  • Ongoing studies are addressing the treatment and prophylaxis of oxaliplatin neurotoxicity.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / pharmacology
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / pharmacology. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacology. Capecitabine. Clinical Trials as Topic. Female. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Metastasis. Neurotoxicity Syndromes / pathology. Paresthesia / chemically induced. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Colorectal Cancer. 2002 May;2(1):54-8 [12453338.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33 [12422305.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2059-69 [12775730.001]
  • [Cites] Clin Colorectal Cancer. 2003 Aug;3(2):121-3 [12952569.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1378-82 [12954576.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13 [14523789.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):531-7 [14745869.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Muscle Nerve. 2004 Mar;29(3):387-92 [14981738.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2084-91 [15169795.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61 [15217938.001]
  • [Cites] Anticancer Drugs. 2004 Aug;15(7):733-5 [15269607.001]
  • [Cites] Anticancer Drugs. 2004 Sep;15(8):767-71 [15494638.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17 [7932825.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):248-9 [9626791.001]
  • [Cites] Toxicol Sci. 1998 Dec;46(2):342-51 [10048138.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1125-8 [10572615.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Oncology (Williston Park). 2000 Dec;14(12 Suppl 11):33-7 [11204661.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):421-2 [11332158.001]
  • [Cites] J Neurophysiol. 2001 May;85(5):2293-7 [11353042.001]
  • [Cites] Anticancer Drugs. 2001 Jul;12(6):525-31 [11459999.001]
  • [Cites] Eur J Cancer. 2001 Dec;37(18):2457-63 [11720843.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1759-66 [11919232.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1767-74 [11919233.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2031-7 [11956262.001]
  • [Cites] Ann Oncol. 2002 May;13(5):716-20 [12075739.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3359-61 [12149316.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3478-83 [12177109.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1307-12 [12663719.001]
  • (PMID = 16168057.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1266024
  •  go-up   go-down


3. Silveira NJ, Varuzza L, Machado-Lima A, Lauretto MS, Pinheiro DG, Rodrigues RV, Severino P, Nobrega FG, Head and Neck Genome Project GENCAPO, Silva WA Jr, de B Pereira CA, Tajara EH: Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. BMC Med Genomics; 2008;1:56
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries.
  • When detected early, HNSCC has a good prognosis, but most patients present metastatic disease at the time of diagnosis, which significantly reduces survival rate.
  • METHODS: Aiming to identify differentially-expressed genes involved in laryngeal squamous cell carcinoma (LSCC) development and progression, we generated individual Serial Analysis of Gene Expression (SAGE) libraries from a metastatic and non-metastatic larynx carcinoma, as well as from a normal larynx mucosa sample.
  • RESULTS: Statistical data analysis identified a subset of 1,216 differentially expressed tags between tumor and normal libraries, and 894 differentially expressed tags between metastatic and non-metastatic carcinomas.
  • Three genes displaying differential regulation, one down-regulated (KRT31) and two up-regulated (BST2, MFAP2), as well as one with a non-significant differential expression pattern (GNA15) in our SAGE data were selected for real-time polymerase chain reaction (PCR) in a set of HNSCC samples.
  • As expected, GNA15 presented a non-significant differential expression pattern when tumor samples were compared to normal tissues.
  • Statistical analysis was effective in identifying differentially expressed genes reportedly involved in cancer development.
  • The differential expression of a subset of genes was confirmed in additional larynx carcinoma samples and in carcinomas from a distinct head and neck subsite.
  • This result suggests the existence of potential common biomarkers for prognosis and targeted-therapy development in this heterogeneous type of tumor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1244-51 [15558013.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):789-97 [15499618.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):127-35 [15685196.001]
  • [Cites] Nat Genet. 2005 Feb;37(2):182-6 [15640797.001]
  • [Cites] Physiol Genomics. 2002 Oct 29;11(2):37-44 [12407185.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] J Cell Biol. 2001 Aug 6;154(3):619-30 [11489919.001]
  • [Cites] Head Neck. 2001 Mar;23(3):238-53 [11428456.001]
  • [Cites] Br J Dermatol. 2001 May;144(5):977-82 [11359384.001]
  • [Cites] Bioinformatics. 2000 Nov;16(11):953-9 [11159306.001]
  • [Cites] J Cell Biol. 2000 Aug 21;150(4):921-8 [10953016.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3220-4 [10918578.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 1):374-81 [10718422.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):151-68 [15657362.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jan;131(1):10-8 [15655179.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8442-50 [15623624.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2779-87 [15546137.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Dec;4(8):637-51 [15578920.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3697-704 [15292061.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 19;258(3):583-91 [10329429.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):457-60 [8944026.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14661-5 [7514177.001]
  • [Cites] Nature. 1993 Dec 2;366(6454):473-5 [7902537.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):249-58 [15352037.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):89-96 [15221650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Cell Mol Life Sci. 2004 Jun;61(11):1372-83 [15170515.001]
  • [Cites] Oncogene. 2004 Apr 1;23(14):2484-98 [14676830.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Mar;130(3):295-302 [15023835.001]
  • [Cites] Oral Oncol. 2004 Apr;40(4):418-26 [14969821.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):55-63 [14729608.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6598-608 [14528285.001]
  • [Cites] Int J Mol Med. 2003 Oct;12(4):429-35 [12964014.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3058-64 [12912957.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):760-70 [12874079.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):754-9 [12874078.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):683-9 [12866027.001]
  • [Cites] Oral Oncol. 2003 Apr;39(3):259-68 [12618198.001]
  • [Cites] Oral Oncol. 2003 Apr;39(3):248-58 [12618197.001]
  • [Cites] Eur J Oral Sci. 2003 Feb;111(1):34-41 [12558806.001]
  • [Cites] Physiol Genomics. 2003 Jan 15;12(2):159-62 [12429865.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8206-19 [12444558.001]
  • [Cites] Biol Direct. 2008;3:22 [18513408.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1482-94 [12237917.001]
  • [Cites] Head Neck. 2002 Sep;24(9):874-87 [12211052.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1713-24 [12200686.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2634-40 [11965536.001]
  • [Cites] Cell Growth Differ. 2002 Apr;13(4):163-71 [11971816.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1184-90 [11861402.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6196-204 [11593428.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Hum Mol Genet. 2001 Sep 15;10(19):2133-41 [11590130.001]
  • [Cites] Cell Oncol. 2008;30(1):63-75 [18219111.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1971-82 [17043662.001]
  • [Cites] Biol Cell. 2006 Aug;98(8):479-90 [16608439.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):136-43 [16181731.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2860-8 [16574107.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4182-90 [16618740.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10089-97 [16492672.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2223-33 [16291593.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):306-16 [16321566.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1570-81 [16249385.001]
  • [Cites] Lab Invest. 2005 Aug;85(8):1024-39 [16205657.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):865-75 [15956244.001]
  • [Cites] Oral Oncol. 2005 Apr;41(4):365-74 [15792608.001]
  • (PMID = 19014460.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2629771
  • [Investigator] Curry PM; de Carvalho MB; Dias-Neto E; Figueiredo DL; Fukuyama EE; Góis-Filho JF; Leopoldino AM; Mamede RC; Michaluart-Junior P; Moreira-Filho CA; Moyses RA; Nóbrega FG; Nóbrega MP; Nunes FD; Ojopi EP; Okamoto OK; Serafini LN; Severino P; Silva AM; Silva WA Jr; Silveira NJ; Souza SC; Tajara EH; Wünsch-Filho V; Zago MA; Amar A; Arap SS; Araújo NS; Araújo-Filho V; Barbieri RB; Bandeira CM; Bastos AU; Braconi MA; Brandão LG; Brandão RM; Canto AL; Carmona-Raphe J; Carvalho-Neto PB; Casemiro AF; Cerione M; Cernea CR; Cicco R; Chagas MJ; Chedid H; Chiappini PB; Correia LA; Costa A; Costa AC; Cunha BR; Curioni OA; Dias TH; Durazzo M; Ferraz AR; Figueiredo RO; Fortes CS; Franzi SA; Frizzera AP; Gallo J; Gazito D; Guimarães PE; Gutierres AP; Inamine R; Kaneto CM; Lehn CN; López RV; Macarenco R; Magalhães RP; Martins AE; Meneses C; Mercante AM; Montenegro FL; Pinheiro DG; Polachini GM; Porsani AF; Rapoport A; Rodini CO; Rodrigues AN; Rodrigues-Lisoni FC; Rodrigues RV; Rossi L; Santos AR; Santos M; Settani F; Silva FA; Silva IT; Silva-Filho GB; Smith RB; Souza TB; Stabenow E; Takamori JT; Tavares MR; Turcano R; Valentim PJ; Vidotto A; Volpi EM; Xavier FC; Yamagushi F; Cominato ML; Correa PM; Mendes GS; Paiva R; Ramos O; Silva C; Silva MJ; Tarlá MV
  •  go-up   go-down


Advertisement
4. Kawecki A, Jagielska B, Falkowski S: [Chemotherapy for metastatic or recurrent laryngeal cancer: tolerance and early results]. Otolaryngol Pol; 2000;54 Suppl 31:21-3
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for metastatic or recurrent laryngeal cancer: tolerance and early results].
  • In the Head and Neck Cancer Department of Cancer Centre in Warsaw between 1994 and 1998 fifty three patients with recurrent or metastatic laryngeal cancer were treated with methotrexate-based chemotherapy.
  • Chemotherapy protocol consist of methotrexate, vinblastine, 5-fluorouracil, bleomycin, cyclophosphamide and steroids used every two weeks.
  • Before treatment, unresectable local recurrence was observed in 35 patient and distant secondaries in 18 others.
  • Tolerance of treatment was acceptable.
  • Presented program is an effective alternative to supportive treatment in patients with recurrent or metastatic laryngeal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974834.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


5. Haigentz M Jr, Silver CE, Hartl DM, Takes RP, Rodrigo JP, Robbins KT, Rinaldo A, Ferlito A: Chemotherapy regimens and treatment protocols for laryngeal cancer. Expert Opin Pharmacother; 2010 Jun;11(8):1305-16
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy regimens and treatment protocols for laryngeal cancer.
  • IMPORTANCE OF THE FIELD: Laryngeal cancer has been the model of curative-intent organ-preserving therapies in clinical oncology.
  • Although the optimal care of patients with laryngeal cancer is truly multidisciplinary, with progressive advances in surgical, radiation, and medical oncology, the development of effective systemic therapies has been a major component of the therapeutic arsenal against laryngeal cancer.
  • AREAS COVERED IN THIS REVIEW: This review will discuss the rapidly evolving roles of chemotherapy in the management of locally advanced and metastatic laryngeal cancer.
  • WHAT THE READER WILL GAIN: The reader will gain a historical perspective on this evolution in treatment and will appreciate current treatment challenges and promising future directions in optimizing therapeutic efficacy in functional larynx preservation and in patient survival.
  • TAKE HOME MESSAGE: The treatment of most patients with laryngeal cancer with systemic therapy represents an opportunity to positively impact functional outcomes with an anatomically and functionally preserved larynx.
  • Future challenges include identification of novel therapies and optimizing therapy protocols for individualized patient care.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Interdisciplinary Communication. Medical Oncology. Pathology, Molecular. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429666.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  •  go-up   go-down


6. Védrine L, Chargari C, Le Moulec S, Fayolle M, Ceccaldi B, Bauduceau O: [Cancer chemotherapy of the upper aerodigestive tract]. Cancer Radiother; 2008 Mar;12(2):110-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer chemotherapy of the upper aerodigestive tract].
  • [Transliterated title] Chimiothérapie des cancers des voies aérodigestives supérieures.
  • Tumours of the upper aerodigestive tract represent the sixth most frequent kind of cancer in France and throughout the world.
  • If the localised forms may be controlled in the long run in two thirds of cases by surgery or radiotherapy, only one third of locally advanced forms are accessible to a cure after association from radiotherapy and chemotherapy.
  • Besides, with a median of survival less than six months, metastatic tumours present a catastrophic spontaneous prognosis among patients with a medical ground that is often heavily deteriorated by prolonged exposure to alcohol and tobacco.
  • Thus, there is a necessity to implement adapted therapeutic strategies to each patient and based on satisfactory proof levels of effectiveness.
  • Optimisation of existing chemotherapy protocols and development of new therapies, in particular of targeted therapies, remain an important objective in the hope to improve results of treatments in locally advanced and metastatic cancers of the oral cavity.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Combined Modality Therapy. Humans. Laryngeal Neoplasms / drug therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187355.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 47
  •  go-up   go-down


7. Lamont EB, Vokes EE: Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol; 2001 May;2(5):261-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in the management of squamous-cell carcinoma of the head and neck.
  • Previously reserved for palliation, chemotherapy is now also a central component of several curative approaches to the management of patients with advanced-stage head and neck cancer.
  • Here we review the results of both induction chemotherapy and chemoradiotherapy trials in patients with curable disease, and chemotherapy trials in patients with recurrent and metastatic disease, and we highlight current areas of investigation.
  • Compared with traditional treatment modalities, chemotherapy given on induction schedules to patients with advanced laryngeal cancer allows greater organ preservation without compromise to survival; when given concomitantly with radiotherapy to patients with resectable or unresectable advanced disease, chemotherapy again improves survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy, Combination. Humans. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local / drug therapy. Randomized Controlled Trials as Topic. Research. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11905780.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 80
  •  go-up   go-down


8. Gagnon PJ, Galderisi C, Page BR, Holland JM: Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx. Head Neck; 2009 Jun;31(6):829-32
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx.
  • BACKGROUND: Angiosarcoma arising after radiation is described in breast cancer but occurs elsewhere.
  • METHODS: This is a case of angiosarcoma developing 5 years after curative therapy for T3N0 squamous cell carcinoma of the supraglottic larynx.
  • Therapy consisted of 3 cycles of induction cisplatin/5-fluorouracil chemotherapy followed by radiotherapy.
  • CT scans assessed the local extent of the tumor and ruled out metastatic disease prior to initiating therapy.
  • RESULTS: Therapy consisted of 4 cycles of paclitaxel chemotherapy.
  • CONCLUSION: This rare therapy-related second malignancy developed after curative larynx-preserving treatment.
  • Paclitaxel was an effective therapy in this setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / therapy. Hemangiosarcoma / etiology. Laryngeal Neoplasms / therapy. Radiotherapy, High-Energy / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. Remission Induction. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 18853452.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Relic A, Scheich M, Stapf J, Voelter C, Hoppe F, Hagen R, Pfreundner L: Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas. Eur Arch Otorhinolaryngol; 2009 Nov;266(11):1799-805
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas.
  • Induction chemotherapy followed by primary radiotherapy in responders is considered an alternative to surgery for advanced cancer of the larynx and hypopharynx (LHC).
  • Comparison of therapeutic approaches is challenging and must respect oncological and functional outcome as well as quality of life during and after treatment.
  • All patients undergoing induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy from 01/96 to 07/05 were included.
  • 28 out of 134 patients underwent salvage surgery after primary treatment with induction chemotherapy and radiotherapy for advanced LHC.
  • 15 patients had laryngectomy (LE) with neck dissection (ND), while 1 patient had lasersurgical partial laryngeal resection with ND for local recurrences.
  • When metastatic disease was present in the neck (4/12), recurrences occurred in 75% during postoperative follow-up.
  • Only 2 out of 20 patients undergoing surgery for histologically proven recurrence after radiochemotherapy (10%) are actually tumor-free and alive after a mean observation time of 43.9 months.
  • ND for suspicious persistent nodal disease after radiochemotherapy can be an over-treatment.
  • In the light of our results, unfavourable outcome after salvage surgery must be pointed out when initially informing patients about different therapeutic options for advanced LHC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Taxoids / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1992 Aug;102(8):934-9 [1495357.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Sep;95(2):213-8 [3108762.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Aug;124(8):871-5 [9708712.001]
  • [Cites] Strahlenther Onkol. 2002 Jul;178(7):363-8 [12163990.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 May;132(5):526-31 [16702569.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):162-5 [7840923.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Dec;126(12):1473-7 [11115285.001]
  • [Cites] Head Neck. 2007 Aug;29(8):715-9 [17274056.001]
  • [Cites] Cancer. 2005 May 15;103(10):2073-81 [15816049.001]
  • [Cites] Am J Otolaryngol. 2005 Nov-Dec;26(6):388-92 [16275407.001]
  • [Cites] Head Neck. 2002 Aug;24(8):759-65 [12203801.001]
  • [Cites] Acta Otolaryngol. 2005 Jan;125(1):91-5 [15799582.001]
  • [Cites] J Laryngol Otol. 1993 Feb;107(2):130-2 [8496645.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1297-301 [7037159.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):662-4 [8988672.001]
  • [Cites] Acta Oncol. 2002;41(1):69-76 [11990522.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):441-8 [17180512.001]
  • [Cites] J Laryngol Otol. 1972 Aug;86(8):785-93 [5044285.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):673-8 [3338032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1418-23 [15050318.001]
  • [Cites] Head Neck. 2003 Oct;25(10):791-8 [12966502.001]
  • [Cites] Laryngoscope. 1980 Jun;90(6 Pt 1):930-45 [7382709.001]
  • [Cites] Laryngoscope. 2006 Jun;116(6):855-8 [16735902.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jun;122(6):892-8 [10828805.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(11):1225-8 [17050318.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Jul;131(1):61-8 [15243559.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Dec;104(12):936-41 [7492064.001]
  • [Cites] Laryngoscope. 1988 Nov;98(11):1205-11 [3054373.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1887-93 [2414254.001]
  • [Cites] Cancer. 1982 Dec 15;50(12 ):2795-801 [6182982.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1864-6 [17003711.001]
  • [Cites] J Laryngol Otol. 1984 Sep;98(9):905-7 [6481227.001]
  • [Cites] Head Neck. 1997 Mar;19(2):116-20 [9059868.001]
  • [Cites] Eur J Surg Oncol. 1989 Aug;15(4):350-6 [2759253.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Apr;124(4):401-6 [9559686.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Apr;112(4):437-9 [3484960.001]
  • [Cites] J Surg Oncol. 1990 Apr;43(4):245-9 [2325423.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1975 Nov-Dec;84(6):833-40 [1053455.001]
  • [Cites] Head Neck. 2005 Aug;27(8):653-8 [16035097.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Jun;115(6):419-24 [16805372.001]
  • [Cites] Radiother Oncol. 1984 Jun;2(1):31-6 [6505273.001]
  • [Cites] Laryngoscope. 1995 Jan;105(1):97-101 [7837923.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Apr;123(4):420-4 [9109791.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2000 Apr;25(2):146-52 [10816221.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9 [12525193.001]
  • [Cites] Head Neck. 2005 Feb;27(2):101-7 [15529321.001]
  • (PMID = 19288123.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; Q20Q21Q62J / Cisplatin; TP protocol
  •  go-up   go-down


10. Pignon JP, Bourhis J, Domenge C, Designé L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet; 2000 Mar 18;355(9208):949-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.
  • BACKGROUND: Despite more than 70 randomised trials, the effect of chemotherapy on non-metastatic head and neck squamous-cell carcinoma remains uncertain.
  • We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment.
  • We included patients with carcinoma of the oropharynx, oral cavity, larynx, or hypopharynx.
  • FINDINGS: The main meta-analysis of 63 trials (10,741 patients) of locoregional treatment with or without chemotherapy yielded a pooled hazard ratio of death of 0.90 (95% CI 0.85-0.94, p<0.0001), corresponding to an absolute survival benefit of 4% at 2 and 5 years in favour of chemotherapy.
  • There was no significant benefit associated with adjuvant or neoadjuvant chemotherapy.
  • Chemotherapy given concomitantly to radiotherapy gave significant benefits, but heterogeneity of the results prohibits firm conclusions.
  • Meta-analysis of six trials (861 patients) comparing neoadjuvant chemotherapy plus radiotherapy with concomitant or alternating radiochemotherapy yielded a hazard ratio of 0.91 (0.79-1.06) in favour of concomitant or alternating radiochemotherapy.
  • Three larynx-preservation trials (602 patients) compared radical surgery plus radiotherapy with neoadjuvant chemotherapy plus radiotherapy in responders or radical surgery and radiotherapy in non-responders.
  • The hazard ratio of death in the chemotherapy arm as compared with the control arm was 1.19 (0.97-1.46).
  • INTERPRETATION: Because the main meta-analysis showed only a small significant survival benefit in favour of chemotherapy, the routine use of chemotherapy is debatable.
  • For larynx preservation, the non-significant negative effect of chemotherapy in the organ-preservation strategy indicates that this procedure must remain investigational.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / therapy. Proportional Hazards Models. Randomized Controlled Trials as Topic. Treatment Outcome


11. Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R: Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer; 2010 Oct;18(10):1263-70
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
  • BACKGROUND/PURPOSE: Oxaliplatin-associated neuropathy remains a dose-limiting toxicity of the standard chemotherapy regimen of oxaliplatin and capecitabine for metastatic colorectal cancer.
  • METHODS: In this open-label pilot feasibility trial, patients with no prior chemotherapy for metastatic colorectal cancer were included.
  • Treatment consisted of capecitabine 1,000 mg/m(2) bid on days 1-14 and oxaliplatin 130 mg/m2 on day 1 of a 21-day cycle.
  • The primary endpoint was feasibility and drug reactions during the infusion.
  • Apart from one patient with laryngeal spasm, no other infusion-related adverse events were observed.
  • While we have observed a relatively low rate of chronic cumulative neuropathy with heated oxaliplatin, this procedure appears not promising enough for us to recommend its further clinical evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Hot Temperature. Neurotoxicity Syndromes / prevention & control
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Pilot Projects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13 [14523789.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33 [12422305.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):4028-9 [17664456.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61 [15217938.001]
  • [Cites] J Peripher Nerv Syst. 2006 Jun;11(2):135-41 [16787511.001]
  • [Cites] Support Care Cancer. 2006 Mar;14(3):223-9 [16021477.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3478-83 [12177109.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1188-9; author reply 1189-90 [18309961.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2006-12 [18421053.001]
  • [Cites] Oncologist. 2007 Mar;12(3):312-9 [17405895.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1288-92 [18349029.001]
  • [Cites] Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46 [15871765.001]
  • [Cites] Qual Life Res. 1997 Apr;6(3):225-36 [9226980.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1759-66 [11919232.001]
  • [Cites] Support Care Cancer. 2006 May;14(5):484-7 [16450089.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2084-91 [15169795.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17 [7932825.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):267-72 [11886004.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] BMC Cancer. 2005 Sep 16;5:116 [16168057.001]
  • [Cites] Ann Oncol. 2004 May;15(5):781-5 [15111347.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1666-72 [17660495.001]
  • (PMID = 19756772.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Blumenschein G, Lu C, Kies M, Glisson B, Papadimitrakopoulou V, Zinner R, Kim E, Gillenwater A, Chiao J, Hong W: Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN). J Clin Oncol; 2004 Jul 15;22(14_suppl):5578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN).
  • In a phase I trial of oral SAHA administered once a day or twice a day, a partial response was observed in a pt with metastatic laryngeal carcinoma.
  • METHODS: Eligible pts must have recurrent and/or metastatic SCCHN unresponsive to or intolerant of conventional chemotherapy (up to two prior chemotherapies including neoadjuvant, adjuvant, and concomitant chemotherapy/radiation); ECOG performance status 0-2; adequate hematologic, hepatic, and renal function; able to swallow capsules; have measurable disease; = 4 weeks from prior chemotherapy, radiation therapy, major surgery or investigational anticancer therapy and have recovered from prior toxicities.
  • 1 pt withdrew consent prior to starting therapy.
  • Prior therapies included radiation in 9 pts and chemotherapy in all 12 pts; 11 patients received platinum, 8 patients received both taxanes and platinum.
  • Toxicity has been acceptable with 1 pt discontinuing therapy for grade 3 anorexia.
  • Other grade 3-4 drug-related toxicities included anemia (n=1), anorexia (n=1), back pain (n=1), fatigue (n=1), and thrombocytopenia (n=3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Labourey JL, Cupissol D, Calais G, Tourani JM, Kohser F, Borel C, Eymard JC, Germann N, Tubiana-Mathieu N: Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol; 2007 Jun;30(3):278-82
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
  • OBJECTIVES: This phase II study was conducted to assess the efficacy of docetaxel plus gemcitabine in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck.
  • PATIENTS AND METHODS: Forty patients with pharynx or larynx cancer were included and treated with an intravenous infusion of docetaxel 75 mg/m2 on day 8 and gemcitabine 1000 mg/m2 day 1 and day 8 every 3 weeks for 6 cycles.
  • RESULTS: Among the 40 patients included, 17 had metastatic disease and 18 had received prior chemotherapy.
  • Three treatment-related deaths due to infection were reported.
  • CONCLUSION: The docetaxel and gemcitabine combination is an active treatment of recurrent or metastatic head and neck cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Laryngeal Neoplasms / drug therapy. Male. Middle Aged. Pharyngeal Neoplasms / drug therapy. Recurrence. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551305.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


14. Taillade L, Alexandre I, Billemont B, Meric JB, Sultan-Amar V, Rixe O: [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma]. Bull Cancer; 2009;96 Suppl 1:S45-55
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
  • [Transliterated title] L'angiogenèse: une nouvelle cible thérapeutique des cancers thoraciques et ORL.
  • Angiogenesis or new blood vessel formation is a complex and fundamental event in the process of tumor growth and metastatic dissemination.
  • These molecules directly inhibit VEGF or the kinase activity of its receptor (VEGFR) and represent a significant therapeutic progress in several solid tumors types.
  • First clinical studies of antiangiogenic agents in thoracic and laryngopharyngeal carcinomas have shown promise mainly in combination with other therapies (chemotherapy, other targeted therapies or radiotherapy).
  • Besides common antiangiogenic therapies-induced adverse events, risks of bleeding caused by tumor necrosis mainly in squamous cell lung carcinomas have been observed during early clinical trials.
  • Assessment of surrogate markers of target inhibition could allow a better selection of patients able to benefit from antiangiogenic treatments eventually combined with chemotherapy or molecules targeting others metabolic pathways.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Lung Neoplasms / blood supply. Neovascularization, Pathologic / drug therapy. Otorhinolaryngologic Neoplasms / blood supply. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Laryngeal Neoplasms / blood supply. Laryngeal Neoplasms / drug therapy. Mesothelioma / blood supply. Mesothelioma / drug therapy. Pharyngeal Neoplasms / blood supply. Pharyngeal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433373.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 49
  •  go-up   go-down


15. Rosati G, Cordio S, Tucci A, Blanco G, Bordonaro R, Reggiardo G, Manzione L: Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology; 2005;69(2):122-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
  • OBJECTIVES: Colorectal cancer is usually diagnosed in elderly patients.
  • Since there is clear evidence that such patients are under-treated and under-represented or even excluded from clinical studies and there are no reliable and prospective data on the feasibility and efficacy of an oxaliplatin (L-OHP)-based chemotherapy in this setting, we have tested the L-OHP plus oral uracil/tegafur (UFT) and oral folinic acid (FA) combination as first-line therapy in patients with advanced or metastatic colorectal cancer (MCRC) aged 70 or older.
  • PATIENTS AND METHODS: Forty-seven patients with advanced or MCRC, aged over 70, were treated with L-OHP 65 mg/m(2) as an intravenous 3-hour infusion on day 1 and 8 plus UFT 300 mg/m(2) and FA 90 mg in 3 divided doses given orally on days 1-14 for each 3-week cycle.
  • RESULTS: All patients were assessable for toxicity and 45 for response to treatment.
  • After a minimum follow-up of 17 months, the median time to disease progression and the median overall survival were 8.0 (95% CI: 6.7-9.3%) and 14.1 (95% CI: 11.0-17.1%) months, respectively.
  • The most common grade 3-4 treatment-related adverse events were diarrhea (17%), neutro- and thrombocytopenia (2%), laryngeal spasm (2%), and peripheral neuropathy (12.7%).
  • No treatment-related deaths occurred.
  • CONCLUSIONS: These results confirmed that this tested chemotherapy combination is active with acceptable tolerability and QoL maintenance in elderly patients with advanced or MCRC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Age Factors. Aged. Aged, 80 and over. Female. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Tegafur / administration & dosage. Treatment Outcome. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118508.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin
  •  go-up   go-down


16. Tanaka A, Ohsawa H, Ikeda H, Koshiba R: [Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina]. Kyobu Geka; 2002 Jul;55(7):537-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina].
  • A 64-year-old male, who had received successful radiotherapy for the previous laryngeal cancer, was admitted to our department for the treatment of a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina.
  • The endotracheal biopsy of the carinal tumor demonstrated squamous cell carcinoma, though preoperative examination of the intrapulmonary tumor was unable to clarify it's pathological type.
  • The intrapulmonary tumor required right upper lobectomy and R2 lymph node dissection as a measure against the possibility of primary lung cancer.
  • Since the endotracheal cancer was diagnosed as an intra mucosal tumor by the preoperative computed tomography (CT) scans and the bronchoscopic examination, laser abrasion therapy to the endotracheal tumor was performed 4 days before the lobectomy of the intrapulmonary tumor.
  • After the pulmonary operation, the intrapulmonary tumor was diagnosed as squamous cell carcinoma without lymph node metastasis, and it was suggested to be a metastatic tumor of the previous laryngeal cancer.
  • Both radiotherapy to the carina and general chemotherapy with docetaxel hydrate and carboplatin were used as adjuvant therapies 36 days after the lobectomy.
  • Laser abrasion therapy to the endotracheal tumor is very useful and safe for the patient, who should then receive pulmonary resection soon after the therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Paclitaxel / analogs & derivatives. Pneumonectomy. Taxoids. Tracheal Neoplasms / surgery
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Humans. Laser Therapy. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12136580.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Garufi C, Nisticò C, Brienza S, Vaccaro A, D'Ottavio A, Zappalà AR, Aschelter AM, Terzoli E: Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol; 2001 Feb;12(2):179-82
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study.
  • PURPOSE: Oxaliplatin (L-OHP), a new platinum analogue, is an active drug in colorectal and ovarian cancer.
  • In this phase II study we explored tolerability and activity of oxaliplatin as a single agent in metastatic breast carcinoma patients.
  • PATIENTS AND METHODS: Fourteen anthracycline pretreated advanced breast cancer patients were enrolled.
  • Three patients developed acute transient laryngeal symptoms.
  • CONCLUSIONS: In this limited experience, oxaliplatin appeared to be well tolerated and moderately active in advanced anthracycline-pretreated breast cancer patients.
  • Combination chemotherapy with other active drugs such as 5-fluorouracil (5-FU), anthracyclines and taxanes should represent the next step of development of this new drug.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11300320.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


18. Wierecky J, Bokemeyer C: [Compression syndromes]. Internist (Berl); 2005 Jan;46(1):9-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common underlying cause is a malignant process, especially lung cancer and lymphoma.
  • Most patients can be treated with appropriately directed chemotherapy or radiotherapy.
  • Accurate diagnosis of the underlying etiology needs to be established before treatment.
  • Only under extreme emergency conditions such as laryngeal or cerebral edema irradiation should be initiated without a histological diagnosis.
  • With the refinement of endovascular stents, percutaneous stenting is being increasingly used as primary treatment modality.
  • Metastatic spinal cord compression is one of the most dreadful complications of cancer.
  • Radiation therapy or surgical treatment should be started as soon as possible.
  • [MeSH-major] Neoplasms / diagnosis. Neoplasms / therapy. Spinal Cord Compression / etiology. Spinal Cord Compression / therapy. Superior Vena Cava Syndrome / diagnosis. Superior Vena Cava Syndrome / therapy
  • [MeSH-minor] Acute Disease. Emergency Medical Services / methods. Humans. Nerve Compression Syndromes / diagnosis. Nerve Compression Syndromes / etiology. Nerve Compression Syndromes / therapy. Practice Guidelines as Topic. Practice Patterns, Physicians'

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1992 Aug 27;327(9):614-9 [1296600.001]
  • [Cites] J Vasc Interv Radiol. 1997 Sep-Oct;8(5):781-8 [9314368.001]
  • [Cites] Eur J Cancer. 1994;30A(3):396-8 [8204366.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2258-62 [3179939.001]
  • [Cites] Clin Radiol. 1993 Dec;48(6):381-5 [8293642.001]
  • [Cites] Neurology. 1989 Jan;39(1):125-6 [2909900.001]
  • [Cites] Radiother Oncol. 2003 Aug;68(2):175-80 [12972313.001]
  • [Cites] Cancer. 1993 May 15;71(10):3006-8 [8490828.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(2):83-9 [9135892.001]
  • [Cites] Ann Neurol. 1978 Jan;3(1):40-51 [655653.001]
  • [Cites] Mayo Clin Proc. 1981 Jul;56(7):407-13 [7253702.001]
  • [Cites] Arch Intern Med. 1993 Feb 8;153(3):384-7 [8381263.001]
  • [Cites] Ann Neurol. 1980 Oct;8(4):361-6 [7436380.001]
  • [Cites] Oncology (Williston Park). 1993 Jun;7(6):61-8; discussion 71-2, 75-7 [8318360.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):959-67 [7607970.001]
  • [Cites] Br J Radiol. 2001 Jan;74(877):15-23 [11227772.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Apr;17(4):384-8 [10773559.001]
  • [Cites] Oncologist. 2004;9(2):188-96 [15047923.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Oct;14(5):338-51 [12555872.001]
  • [Cites] Chest. 2003 Mar;123(3):809-12 [12628882.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1613-24 [9552073.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1502-8 [2311062.001]
  • [Cites] Am Rev Respir Dis. 1990 May;141(5 Pt 1):1114-8 [2339833.001]
  • [Cites] Lung Cancer. 2004 Feb;43(2):209-14 [14739042.001]
  • [Cites] Lung Cancer. 1993 Dec;10(3-4):221-8 [7521265.001]
  • (PMID = 15592802.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 28
  •  go-up   go-down


19. Burns P, Sheahan P, Doody J, Kinsella J: Clavicular osteomyelitis: a rare complication of head and neck cancer surgery. Head Neck; 2008 Aug;30(8):1124-7
MedlinePlus Health Information. consumer health - E. Coli Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clavicular osteomyelitis: a rare complication of head and neck cancer surgery.
  • BACKGROUND: We report the 10th case in the English-language literature describing clavicular osteomyelitis that presented after radical treatment for laryngeal carcinoma and discuss the pertinent diagnostic and therapeutic measures.
  • The differential diagnosis included tumor recurrence, metastatic bone disease, and postradiotherapy complications.
  • METHODS AND RESULTS: A 45-year-old man who was a heavy smoker and known drug abuser presented with acute airway compromise and was diagnosed with squamous cell carcinoma involving the glottis and subglottis.
  • After aggressive treatment, the patient remains disease free.
  • Aggressive surgical debridement and antibiotic therapy remains the mainstay of treatment.
  • Prompt diagnosis and treatment are mandatory due to the potential life-threatening complications associated with the condition.
  • [MeSH-minor] Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Humans. Laryngeal Neoplasms / therapy. Laryngectomy. Male. Middle Aged. Neck Dissection. Radiotherapy, Adjuvant. Staphylococcal Infections / diagnosis. Surgical Stomas. Surgical Wound Dehiscence / microbiology. Surgical Wound Dehiscence / surgery. Thyroidectomy

  • Genetic Alliance. consumer health - Osteomyelitis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18228522.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of head and neck cancers.
  • These patients include a mixture of presentations including primary, recurrent, and metastatic lesions.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.
  • Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers.
  • Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT.
  • Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment.
  • Laryngeal cancers, comprising 171 patients in this group, obtained a durable complete response rate of 89% with up to a 16-year follow-up.
  • Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck.
  • It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Rajendran ES: Homeopathy as a supportive therapy in cancer. Homeopathy; 2004 Apr;93(2):99-102
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homeopathy as a supportive therapy in cancer.
  • Three cases of cancer in which homeopathic treatment was used in a complementary role are described: A 64-year-old male with metastatic adenocarcinoma of the rectum.
  • There was intense pain not relieved by available treatment.
  • A 70-year-old male with carcinoma of the larynx.
  • He had been receiving homeopathic treatment after the diagnosis because of his faith in it.
  • He was advised to have surgery, radiation and chemotherapy, which he underwent immediately.
  • This treatment was followed by homeopathic constitutional treatment.
  • Homeopathic medicines prescribed on constitutional grounds may play a useful role in supportive and palliative for patients with malignant disease.
  • [MeSH-major] Homeopathy. Neoplasms / therapy. Pain Management
  • [MeSH-minor] Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Facial Neoplasms / therapy. Female. Humans. Laryngeal Neoplasms / therapy. Male. Pain / etiology. Rectal Neoplasms / therapy. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15139095.001).
  • [ISSN] 1475-4916
  • [Journal-full-title] Homeopathy : the journal of the Faculty of Homeopathy
  • [ISO-abbreviation] Homeopathy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


22. Al-Zahid S, Singh V: Tuberculous cervical lymphadenitis in a patient with laryngeal carcinoma. J Laryngol Otol; 2010 Jan;124(1):90-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculous cervical lymphadenitis in a patient with laryngeal carcinoma.
  • OBJECTIVE: We report an extremely rare presentation of concomitant tuberculous cervical lymphadenitis in a patient with carcinoma of the larynx.
  • The patient was treated with radiotherapy to the larynx and concomitant anti-tuberculosis chemotherapy.
  • Five months following treatment, there was no sign of laryngeal cancer recurrence; however, the patient continued to have a productive cough and night sweats.
  • CONCLUSION: To our knowledge, this is the first report of a laryngeal carcinoma with concurrent tuberculous cervical lymphadenitis.
  • In the face of an unhelpful fine needle aspiration cytology examination, an assumption of metastatic neck disease could have been made.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Laryngeal Neoplasms / complications. Tuberculosis, Lymph Node / complications
  • [MeSH-minor] Aged. Antitubercular Agents / therapeutic use. Biopsy. Humans. Lymph Nodes / pathology. Magnetic Resonance Imaging. Male. Treatment Outcome. Vocal Cords / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646297.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


23. Ferlito A, Silver CE, Rinaldo A, Smith RV: Surgical treatment of the neck in cancer of the larynx. ORL J Otorhinolaryngol Relat Spec; 2000 Jul-Aug;62(4):217-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of the neck in cancer of the larynx.
  • Current concepts in management of the clinically negative and clinically positive neck in laryngeal cancer are reviewed.
  • Immunohistochemistry or molecular analysis may detect metastatic involvement not apparent by light microscopy.
  • The surgeon should be aware of the relatively high incidence of micrometastases in patients with laryngeal cancer to establish optimal treatment approaches.
  • Elective treatment of the neck is recommended for supraglottic tumors staged T2 or higher, and glottic or subglottic tumors staged T3 or higher.
  • Elective neck dissection provides important information for prognostic purposes and therapeutic decisions, by establishing the presence, number, location and nature of occult lymph node metastases.
  • The selective lateral neck dissection (levels II, III and IV), unilateral or bilateral, is the procedure of choice for elective treatment.
  • Paratracheal nodes (level VI) should be dissected in cases of advanced glottic and subglottic cancer.
  • More advanced disease has been treated in this manner often in association with adjuvant chemotherapy and/or irradiation.
  • While the benefit of adjuvant treatment is difficult to assess, it appears most useful in cases with extranodal spread of disease, a factor associated with the worst prognosis.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Lymph Node Excision. Neck / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10859523.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 114
  •  go-up   go-down


24. Abo H, Tsukuda M, Matsuda H, Horiuchi C, Taguchi T, Watanabe M, Niho T: [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1707-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx].
  • We report two successful remnant and recurrent cases of head and neck cancer treated with S-1.
  • Case 1, a 52-year-old man, was diagnosed as supraglottic laryngeal carcinoma (T3N2cM0, squamous cell carcinoma: SCC) on January 25, 2000, and concurrent chemoradiotherapy (CCRT) was applied.
  • After the treatment, a remnant tumor in the larynx was found by biopsy.
  • Pulmonary metastasis was detected by chest CT on June 14, 2001, and the administration of S-1 was started.
  • The administration of S-1 is still continuing and remnant tumors have not been found.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838032.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


25. Rydzewski B, Matusiak M: [Osteosarcoma of the larynx]. Otolaryngol Pol; 2005;59(2):285-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteosarcoma of the larynx].
  • The authors present a case of rare laryngeal neoplasm--osteosarcoma, which generated many diagnostic and treatment difficulties.
  • No cancer nor tuberculosis was found".
  • After the physiologic consultations and with positive tuberculin test the tuberculocidal treatment was applied, but it bought no success.
  • The larynx was split then, intraoperative histopathological examination gave the result: "Cellulae carcinomatosae".
  • Postoperative immunohistochemical examination was "Osteosarcoma of larynx".
  • The patient was not evaluated for radio- or chemotherapy.
  • During the postoperative course some metastatic lymph nodes on the left side of the neck and in lungs were detected.
  • Patient noted to chemotherapy.
  • [MeSH-major] Laryngeal Neoplasms. Osteosarcoma
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Humans. Laryngectomy. Male

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095104.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement